SLRX: Salarius Pharmaceuticals, Inc. Stock

by  •  • Comments Off on SLRX: Salarius Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3.27
Enterprise Value ($M) 0.32
Book Value ($M) 2.92
Book Value / Share 2.03
Price / Book 1.12
NCAV ($M) 2.89
NCAV / Share 2.00
Price / NCAV 1.13

Profitability (mra)
Return on Invested Capital (ROIC) -1.53
Return on Assets (ROA) -0.76
Return on Equity (ROE) -0.94

Liquidity (mrq)
Quick Ratio 4.09
Current Ratio 4.09

Balance Sheet (mrq) ($M)
Current Assets 3.82
Assets 3.86
Liabilities 0.93
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Armistice Capital, Llc 4.99 -82.29

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION R
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPOR
2024-04-22 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. 1)
2024-03-22 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ———————————— (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 4,747 41,301 11.49
2025-02-03 10,488 44,176 23.74
2025-01-31 14,082 43,979 32.02
2025-01-30 15,481 55,336 27.98

(click for more detail)

Similar Companies
SHPH – Shuttle Pharmaceuticals Holdings, Inc. SILO – Silo Pharma, Inc.
SLGL – Sol-Gel Technologies Ltd. SLS – SELLAS Life Sciences Group, Inc.
SNDL – SNDL Inc.


Financial data and stock pages provided by
Fintel.io